导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.83% | 1984/4773 |
| 近一周 | -1.88% | 3059/5465 |
| 近一月 | -1.05% | 1007/5421 |
| 近一季 | -3.77% | 1683/5231 |
| 近半年 | -7.35% | 3325/4920 |
| 近一年 | 5.58% | 1691/4394 |
| 近两年 | 30.11% | 2267/2954 |
| 近三年 | 20.42% | 1470/2253 |
| 成立以来 | 79.10% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.29% 761/4961 |
1.80% 2990/5312 |
- - |
- - |
| 2025 | 6.39% 2964/4813 |
-4.39% 3171/3635 |
0.95% 2523/4076 |
6.84% 3502/4524 |
3.17% 729/4813 |
| 2024 | 18.42% 604/3463 |
9.15% 144/2808 |
1.86% 436/3014 |
6.95% 2827/3129 |
-0.41% 1415/3463 |
| 2023 | 6.17% 174/2656 |
14.86% 230/2280 |
1.18% 232/2385 |
-3.29% 888/2515 |
-5.54% 1389/2655 |
| 2022 | -11.67% 250/2207 |
-10.32% 388/1919 |
2.55% 1289/2016 |
-9.18% 250/2113 |
5.75% 440/2208 |
| 2021 | 24.34% 121/1822 |
2.23% 224/1255 |
3.29% 976/1330 |
16.42% 73/1466 |
1.14% 998/1822 |
| 2020 | 7.99% 859/1250 |
-9.26% 665/1028 |
-0.33% 1015/1067 |
9.01% 684/1164 |
9.54% 634/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实央企创新驱动ETF联接A VS. 长安沪深300非周期A(740101) |